Pharmacotherapy of social anxiety disorder: what does the evidence tell us?
- PMID:17092192
Pharmacotherapy of social anxiety disorder: what does the evidence tell us?
Abstract
The treatment goals for social anxiety disorder (SAD) are to reduce fear, avoidance, physical distress, disability, and comorbidity. This review illustrates some of the primary studies used to evaluate efficacy of treatments for SAD. The selective serotonin reuptake inhibitors (SSRIs) paroxetine, sertraline, fluoxetine, fluvoxamine, and escitalopram and the serotonin-norepinephrine reuptake inhibitor venlafaxine are effective treatments. They have the additional benefit of being able to treat comorbid conditions. For people who do not respond to serotonin reuptake inhibitors, treatment options include benzodiazepines (clonazepam, alprazolam, and bromazepam), alpha2delta calcium-channel blockers (gabapentin and pregabalin), reversible inhibitors of monoamine oxidase A (moclobemide, although agents in this class are not available in the United States), antiepileptics (levetiracetam), and atypical antipsychotics (olanzapine). The irreversible monoamine oxidase inhibitor phenelzine can be considered an effective third-line therapy. Combination treatments may be beneficial, but more research is needed. Benefits of beta-blockers (propranolol and atenolol) are limited to performance anxiety. Botulinum toxin A may be an effective augmentation treatment option for severe axillary hyperhidrosis in patients with SAD. Studies show that patients with SAD who are maintained on paroxetine, sertraline, or clonazepam have a low relapse rate.
Similar articles
- [Neurobiology and pharmacotherapy of social phobia].Aouizerate B, Martin-Guehl C, Tignol J.Aouizerate B, et al.Encephale. 2004 Jul-Aug;30(4):301-13. doi: 10.1016/s0013-7006(04)95442-5.Encephale. 2004.PMID:15538306Review.French.
- The psychopharmacology of social phobia and comorbid disorders.Rosenbaum JF, Pollock RA.Rosenbaum JF, et al.Bull Menninger Clin. 1994 Spring;58(2 Suppl A):A67-83.Bull Menninger Clin. 1994.PMID:7913851Review.
- Paroxetine treatment of generalized anxiety disorder.Sheehan DV, Mao CG.Sheehan DV, et al.Psychopharmacol Bull. 2003 Spring;37 Suppl 1:64-75.Psychopharmacol Bull. 2003.PMID:14566202Review.
- Therapeutic strategies for the patient with treatment-resistant anxiety.Coplan JD, Tiffon L, Gorman JM.Coplan JD, et al.J Clin Psychiatry. 1993 May;54 Suppl:69-74.J Clin Psychiatry. 1993.PMID:8509358Review.
- Treatment of Anxiety Disorders: A Systematic Review [Internet].Swedish Council on Health Technology Assessment.Swedish Council on Health Technology Assessment.Stockholm: Swedish Council on Health Technology Assessment (SBU); 2005 Nov. SBU Yellow Report No. 171/1+2.Stockholm: Swedish Council on Health Technology Assessment (SBU); 2005 Nov. SBU Yellow Report No. 171/1+2.PMID:28876726Free Books & Documents.Review.
Cited by
- Psychiatric comorbidity and quality of life in patients with post-stroke emotional incontinence.Choi DH, Jeong BO, Kang HJ, Kim SW, Kim JM, Shin IS, Kim JT, Park MS, Cho KH, Yoon JS.Choi DH, et al.Psychiatry Investig. 2013 Dec;10(4):382-7. doi: 10.4306/pi.2013.10.4.382. Epub 2013 Oct 16.Psychiatry Investig. 2013.PMID:24474987Free PMC article.
- Immediate post-defeat infusions of the noradrenergic receptor antagonist propranolol impair the consolidation of conditioned defeat in male Syrian hamsters.Gray CL, Krebs-Kraft DL, Solomon MB, Norvelle A, Parent MB, Huhman KL.Gray CL, et al.Physiol Behav. 2015 Dec 1;152(Pt A):56-61. doi: 10.1016/j.physbeh.2015.09.010. Epub 2015 Sep 11.Physiol Behav. 2015.PMID:26367452Free PMC article.
- New perspectives on beta-adrenergic mediation of innate and learned fear responses to predator odor.Do Monte FH, Canteras NS, Fernandes D, Assreuy J, Carobrez AP.Do Monte FH, et al.J Neurosci. 2008 Dec 3;28(49):13296-302. doi: 10.1523/JNEUROSCI.2843-08.2008.J Neurosci. 2008.PMID:19052221Free PMC article.
- Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV.Garakani A, et al.Front Psychiatry. 2020 Dec 23;11:595584. doi: 10.3389/fpsyt.2020.595584. eCollection 2020.Front Psychiatry. 2020.PMID:33424664Free PMC article.Review.
- Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety.Fliegel DK, Lichenstein SD.Fliegel DK, et al.Psychiatry Res Commun. 2022 Dec;2(4):100074. doi: 10.1016/j.psycom.2022.100074. Epub 2022 Sep 13.Psychiatry Res Commun. 2022.PMID:36875967Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical